dia playback is unsupported on your device media caption turing pharmaceuticals boss martin shkreli had previously defended the price riise judging by social media , martin shkreli , the 32-year-old chief executive of turing pharmaceuticals , may be the most hated man in america right now . newline_char other drugs companies have made similar moves raising the price of niche products , but few have so publicly and so unapologetically answered critics . newline_char in 2006 , mr shkreli started his own hedge fund , elea capital management . newline_char image copyright thinkstock image caption shkreli moved into the pharmaceutical industry after working as a hedge fund manager a rocky start in pharmaceuticals turing was not mr shkreli 's first foray into the pharmaceutical industry . story_separator_special_tag — that turing pharmaceuticals hiked the cost of a drug called daraprim by 5,000 % last month . newline_char but there 's a much bigger problem than shkreli here : the skyrocketing cost of generic drugs . newline_char here 's an incredible sentence from an abc news report from this past may — on three other generic drugs that have seen their prices skyrocket in the past year . newline_char one 49-year-old patient suffering from a painful condition called endometriosis said the cost of her treatment had grown 6,500 % between 2010 and 2015 . newline_char " there 's a mix of reasons for these soaring prices , but the most important factor is that companies like turing are cornering the market on certain generic drugs , and then using their near-monopoly power to hike prices . newline_char and given the relatively small numbers of people affected by each of these drug hikes , there has n't been much attention on the issue — even though the national community pharmacists association has flagged dozens of generic drugs that have seen their costs similarly skyrocket in the past year .
